Skip to main content
. 2016 Apr 11;2016:6594039. doi: 10.1155/2016/6594039

Table 2.

Associations between WWOX CNV-67048 copy numbers and EOC risk and stages.

CNV-67048 genotypes n (%) n (%) P Crude
OR (95% CI)
Adjusted
OR (95% CI)a
Case-control study Patients Controls
Total number 549 571
 2-copy 339 (61.75) 397 (69.53) 0.005 1.000 (ref.) 1.000 (ref.)
 1-copy 181 (32.97) 160 (28.02) 1.325 (1.024–1.714) 1.268 (0.967–1.663)
 0-copy 29 (5.28) 14 (2.45) 2.425 (1.261–4.665) 2.198 (1.111–4.348)
 1 + 0-copy 210 (38.25) 174 (30.47) 1.413 (1.103–1.811) 1.346 (1.037–1.747)
Trend test P value 0.002 0.009

Case only study Stages III + IV Stages I + II
Total number 506 43 0.308
 2-copy 309 (61.07) 30 (69.77) 1.000 (ref.) 1.000 (ref.)
 1-copy 168 (33.20) 13 (30.23) 1.255 (0.637–2.470) 1.330 (0.655–2.701)
 0-copy 29 (5.73) 0 (0.00)
 1 + 0-copy 197 (38.93) 13 (30.23) 1.471 (0.749–2.888) 1.554 (0.771–3.129)
Trend test P value 0.129 0.112

aAdjusted in a logistic regression model that included age, age at menarche, number of births, menstrual history, oral contraceptive use, family history of cancer, smoking status, and alcohol intake.